Beijing, Sept 2, 2026 — China’s Center for Medical Device Evaluation (CMDE) released six draft registration and review guidelines covering gamma beam stereotactic radiotherapy systems, implantable cardiac pacemakers, and hemodynamic monitoring products, opening a public comment period through Oct 8, 2026, as regulators tighten technical standards for high-risk medical equipment.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Center for Medical Device Evaluation (CMDE), National Medical Products Administration |
| Document | Six Registration and Review Guidelines for Medical Devices (Draft for Comments) |
| Total guidelines | 6 |
| Comment deadline | Oct 8, 2026 |
| Lead guideline | Gamma Beam Stereotactic Radiotherapy System Registration and Review Guiding Principles |
Guidelines and Contacts
| No. | Guideline | Contact | Phone | |
|---|---|---|---|---|
| 1 | Gamma Beam Stereotactic Radiotherapy System | He Liping | help@cmde.org.cn | 010-86452614 |
| 1 | Medical Electron Linear Accelerator | He Liping | help@cmde.org.cn | 010-86452614 |
| 2 | Electronic Infusion Pump | Zhong Youjin | zhongyj@cmde.org.cn | 010-86452610 |
| 2 | Implantable Cardiac Pacemaker (2026 Revision) | Zhong Youjin | zhongyj@cmde.org.cn | 010-86452610 |
| 3 | Implantable Pacemaker Lead (2026 Revision) | Wang Ying | wangying@cmde.org.cn | 010-86452612 |
| 4 | Hemodynamic Monitoring Products | Zhang Song | zhangsong@cmde.org.cn | 010-86452608 |
Market Impact Analysis
The six draft guidelines span high-value therapeutic and monitoring modalities, signaling CMDE’s intent to standardize market entry for devices with significant clinical and capital investment implications. The inclusion of gamma beam stereotactic radiotherapy systems and medical electron linear accelerators reflects growing regulatory attention to precision radiation oncology as China expands cancer treatment infrastructure. By establishing clear registration benchmarks for these advanced systems, regulators are reducing uncertainty for domestic and international radiotherapy equipment makers navigating a market with rising demand but historically uneven technical review standards.
The 2026 revisions for implantable cardiac pacemakers and pacemaker leads suggest updated safety and performance requirements, potentially incorporating lessons from recent post-market surveillance data and international standards evolution. For cardiovascular device manufacturers, the revised guidelines may introduce new electrical safety, biocompatibility, or longevity testing protocols that could require design modifications or additional validation studies for pending applications.
The electronic infusion pump and hemodynamic monitoring product guidelines address categories with high hospital penetration and direct patient safety impact. Standardized registration requirements for these devices are likely to accelerate review timelines while elevating the compliance floor for mid-tier domestic manufacturers that have historically relied on fragmented local approvals.
Forward-Looking Statement
Industry analysts expect the finalized six guidelines to take effect in early 2027, establishing the technical baseline for device registrations across radiation oncology, cardiac rhythm management, and critical care monitoring through the remainder of the decade. The Oct 8 comment deadline leaves a five-week window for industry input, suggesting regulators aim to move quickly to close regulatory gaps in these high-priority categories. Companies with pending applications or pipeline products in the covered areas should review the drafts immediately, as the 2026 revisions for pacemakers and leads may introduce requirements not anticipated under previous guidance. The bulk release approach reinforces CMDE’s shift toward systematic, catalog-wide standardization rather than reactive, product-specific rulemaking.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260904134545142.html